REGENX Biosciences, LLC Consortium Awarded $7.7 Million Grant From EC for the Advancement of Clinical Development Program Using NAV™ rAAV8 Vectors
3/27/2013 10:27:27 AM
More...
|
REGENX Biosciences, LLC Receives FDA Orphan Designation for Treatment of Familial Hypercholesterolemia Using NAV(TM) rAAV8 Vectors
4/10/2012 8:51:08 AM
More...
|
REGENX Biosciences, LLC and Asklepios BioPharmaceutical, Inc. Enter Into Agreement for the Development of Treatments for Hemophilia A Using NAV(TM) rAAV8 Vectors
3/8/2012 8:49:39 AM
More...
|